Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Mark

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
International Journal of Sports Physical Therapy|November 6, 2024
Task-Driven Neurophysiological qEEG Baseline Performance Capabilities in Healthy, Uninjured Division-I College AthletesRobert E Mangine, Thomas G Palmer, James A Tersak, et al.
Clinical Genitourinary Cancer|January 29, 2019
Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot StudyMichael Mark, Dirk Klingbiel, Ulrich Mey, et al.
Journal of Medicinal Chemistry|December 7, 2007
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetesMatthias Eckhardt, Elke Langkopf, Michael Mark, et al.
Clinical Laboratory|September 25, 2012
Effects of the DPP-4 inhibitor, linagliptin, in diet-induced obese rats: a comparison in naive and exenatide-treated animalsSteven P Vickers, Sharon C Cheetham, Gareth D Birmingham, et al.
Cancer Treatment and Research Communications|June 12, 2026
Real-world testing practices, treatment patterns, and outcomes of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor-mutated advanced/metastatic non-small cell lung cancer: An international studyJens Samol, Ingel Demedts, Mustafa Erman, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2021
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trialPatrizia Froesch, Michael Mark, Sacha I Rothschild, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 27, 2024
Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparisonKristen Johnson, Barbara Stoffel, Michael Schwitter, et al.
International Journal of Sports Physical Therapy|May 5, 2026
Countermovement Jump and Quantitative Electroencephalography Assessment in Division I Football Athletes: An Exploratory Neurophysiological Study of Return‑to‑Play ReadinessRobert E Mangine, Bradley T Jacobs, James A Tersak, et al.
Scientific Reports|February 27, 2020
Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5/6 nephrectomyDenis Delić, Franziska Wiech, Richard Urquhart, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2024
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17Michael Mark, Patrizia Froesch, Katrin Gysel, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
International Journal of Sports Physical Therapy|November 6, 2024
Task-Driven Neurophysiological qEEG Baseline Performance Capabilities in Healthy, Uninjured Division-I College AthletesRobert E Mangine, Thomas G Palmer, James A Tersak, et al.
Clinical Genitourinary Cancer|January 29, 2019
Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot StudyMichael Mark, Dirk Klingbiel, Ulrich Mey, et al.
Journal of Medicinal Chemistry|December 7, 2007
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetesMatthias Eckhardt, Elke Langkopf, Michael Mark, et al.
Clinical Laboratory|September 25, 2012
Effects of the DPP-4 inhibitor, linagliptin, in diet-induced obese rats: a comparison in naive and exenatide-treated animalsSteven P Vickers, Sharon C Cheetham, Gareth D Birmingham, et al.
Cancer Treatment and Research Communications|June 12, 2026
Real-world testing practices, treatment patterns, and outcomes of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor-mutated advanced/metastatic non-small cell lung cancer: An international studyJens Samol, Ingel Demedts, Mustafa Erman, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2021
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trialPatrizia Froesch, Michael Mark, Sacha I Rothschild, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 27, 2024
Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparisonKristen Johnson, Barbara Stoffel, Michael Schwitter, et al.
International Journal of Sports Physical Therapy|May 5, 2026
Countermovement Jump and Quantitative Electroencephalography Assessment in Division I Football Athletes: An Exploratory Neurophysiological Study of Return‑to‑Play ReadinessRobert E Mangine, Bradley T Jacobs, James A Tersak, et al.
Scientific Reports|February 27, 2020
Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5/6 nephrectomyDenis Delić, Franziska Wiech, Richard Urquhart, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2024
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17Michael Mark, Patrizia Froesch, Katrin Gysel, et al.
Pageof 9